Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
BMJ Open ; 6(10): e011774, 2016 10 31.
Article in English | MEDLINE | ID: mdl-27799240

ABSTRACT

OBJECTIVES: To describe the effect of in utero exposure to the buprenorphine+naloxone combination product in a rural and remote population. SETTING: A district hospital that services rural and remote, fly-in communities in Northwestern Ontario, Canada. PARTICIPANTS: A retrospective cohort study was conducted of 855 mother infant dyads between 1 July 2013 and 30 June 2015. Cases included all women who had exposure to buprenorphine+naloxone during pregnancy (n=62). 2 control groups were identified; the first included women with no opioid exposure in pregnancy (n=618) and the second included women with opioid exposure other than buprenorphine+naloxone (n=159). Women were excluded if they had multiple pregnancy or if they were part of a methadone programme (n=16). The majority of women came from Indigenous communities. OUTCOMES: The primary outcomes were birth weight, preterm delivery, congenital anomalies and stillbirth. Secondary neonatal outcomes included gestational age at delivery, Apgar scores at 1 and 5 min, NAS Score >7 and treatment for neonatal abstinence syndrome (NAS). Secondary maternal outcomes included the number of caesarean sections, postpartum haemorrhages, out of hospital deliveries and transfer of care to tertiary centres. RESULTS: No difference was found in the primary outcomes or in the Apgar score and caesarean section rate between in utero buprenorphine+naloxone exposure versus no opioid exposure in pregnancy. Compared to women taking other opioids, women taking buprenorphine+naloxone had higher birthweight babies (p=0.001) and less exposure to marijuana (p<0.001) during pregnancy. CONCLUSIONS: Retrospective data suggest that there likely is no harm from taking buprenorphine+naloxone opioid agonist treatment in pregnancy. Larger, prospective studies are needed to further assess safety.


Subject(s)
Buprenorphine/adverse effects , Naloxone/adverse effects , Narcotic Antagonists/adverse effects , Neonatal Abstinence Syndrome/epidemiology , Opioid-Related Disorders/epidemiology , Pregnancy Complications/chemically induced , Pregnant Women , Rural Population , Adult , Apgar Score , Birth Weight , Female , Humans , Infant, Newborn , Ontario/epidemiology , Pregnancy , Pregnancy Complications/epidemiology , Pregnant Women/ethnology , Pregnant Women/psychology , Retrospective Studies , Rural Population/statistics & numerical data , Treatment Outcome
3.
Inflamm Allergy Drug Targets ; 12(5): 297-307, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23713607

ABSTRACT

Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen, which is the major cause of severe chronic lung infection in cystic fibrosis patients. It is also responsible for systemic infections in immunocompromised individuals and those presenting with significant pulmonary conditions in intensive care units. This microorganism has the capacity to initiate severe inflammation in infected lungs resulting in detrimental tissue damage. We have hypothesized that Syk protein tyrosine kinase mediates lung epithelial cellular responses to P. aeruginosa infection, and that a naturally occurring non-toxic Syk inhibitor piceatannol can protect infected human cells against the deleterious effects associated with this infection. We infected Syk-positive H292 or Syk-negative A549 human lung epithelial cell lines with P. aeruginosa and assessed the resulting cellular responses, i.e. production of proinflammatory cytokines, adhesion molecule expression, generation of reactive oxygen species, and apoptosis of infected cells, utilizing a multiplex bead-based immunoassay and flow cytometry. We also studied the internalization of P. aeruginosa using the gentamicin exclusion assay. We found that the piceatannol treatment significantly suppressed inflammation, oxidative stress and apoptosis in H292, but not in A549 cells implicating Syk participation in the regulation of the pathological processes induced by P. aeruginosa infection. Intriguingly, piceatannol was able to down-regulate the internalization of P. aeruginosa by both Syk-positive and Syk-negative cell lines, implying that the mechanisms of action of this compound extend beyond Syk inhibition. As piceatannol can interfere with several mechanisms of bacterial pathogenesis this natural compound deserves further study as a potential therapeutic option in P. aeruginosa infection.


Subject(s)
Lung/immunology , Pseudomonas Infections/drug therapy , Pseudomonas aeruginosa/immunology , Respiratory Mucosa/drug effects , Stilbenes/pharmacology , Apoptosis/drug effects , Cell Line , Cell Separation , Cytokines/metabolism , Endocytosis/drug effects , Flow Cytometry , Humans , Inflammation Mediators/metabolism , Intercellular Adhesion Molecule-1/metabolism , Intracellular Signaling Peptides and Proteins/antagonists & inhibitors , Lung/microbiology , Oxidative Stress/drug effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Pseudomonas Infections/immunology , Respiratory Mucosa/immunology , Syk Kinase
SELECTION OF CITATIONS
SEARCH DETAIL
...